Clinical Trials Directory

Trials / Unknown

UnknownNCT01380262

Pre-emptive Low-dose Doxycycline During Anti-EGFR Treatment

Prospective Phase II Study on Skin Toxicity on Low-Dose Doxycycline in Metastatic Colorectal Cancer Patients During Cetuximab and Panitumumab Treatment

Status
Unknown
Phase
Study type
Observational
Enrollment
40 (estimated)
Sponsor
Maria Sklodowska-Curie National Research Institute of Oncology · Academic / Other
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Not accepted

Summary

Up to 60% of patients with metastatic colorectal cancer can be treated with one of monoclonal antibodies targeted against epidermal growth factor receptor (EGFR). This treatment is associated with a specific spectrum of toxicity: acne-like rash from limited up to erythema, often with severe pruritus, sometimes combined with other types of skin toxicities (hair and nail changes). Previously in STEPP study investigators shown that pre-emptive treatment with oral doxycycline (200 mg daily), topical steroids and sun blockers reduces the number of more severe skin side effects of panitumumab. The study is designed to described the profile of skin toxicity of EGFR blocking drugs combined with low-dose doxycycline (100 mg daily) used in the pre-emptive manner.

Detailed description

Patients with metastatic colorectal cancer treated with cetuximab or panitumumab usually develop the skin toxicity which can impair patients' quality of life as well as limit the treatment. We designed this trial to assess the effect of simplified protocol of pre-emptive treatment on the observed skin toxicities during cetuximab and panitumumab treatment of colorectal cancer. The study is a cohort observational, single center study which should result in estimation of particular types of toxicities, especially occurence of more severe (grade 2 and 3) side effects and assess the tolerance of doxycyline in the prolonged administration. The observation in the study is biweekly and is continued up to 8 weeks.

Conditions

Timeline

Start date
2010-06-01
Primary completion
2011-09-01
Completion
2011-09-01
First posted
2011-06-27
Last updated
2011-06-27

Locations

1 site across 1 country: Poland

Source: ClinicalTrials.gov record NCT01380262. Inclusion in this directory is not an endorsement.

Pre-emptive Low-dose Doxycycline During Anti-EGFR Treatment (NCT01380262) · Clinical Trials Directory